Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer
Recruiting · NCT05656794 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Radiotherapy
What this trial is about
This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.
Who can take part
Age range
18 Years to 100 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Histologically-proven prostate cancer
- Presence of low-volume or high-volume metastases (high volume defined as the presence of visceral metastases or ≥4 bone lesions with at least 1 lesion beyond the vertebral bodies and pelvis.)
- Planned to or receiving systemic treatment ADT +/- ARAT as per physician discretion (Previous chemotherapy allowed if completed more than 6 weeks prior to randomization.)
- Planned for EBRT
- ECOG 0 or 1
- Age 18 years or older
Exclusion criteria
- Prior radiotherapy to pelvis
- Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
- Any condition where radiotherapy is contraindicated
Where it is running
1 location listed.
- University Health Network, Princess Margaret Hospital - Toronto, Ontario, Canada